- Home
- DMAC
as 07-26-2024 4:00pm EST
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 123.8M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 67.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.94 - $3.81 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of DiaMedica Therapeutics Inc. (DMAC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Von Koch Thomas | DMAC | 10% Owner | Jun 28 '24 | Buy | $2.50 | 1,200,000 | $3,000,000.00 | 5,526,435 | SEC Form 4 |
| STAHLBERG JAN | DMAC | 10% Owner | Jun 28 '24 | Buy | $2.50 | 1,200,000 | $3,000,000.00 | 5,221,608 | SEC Form 4 |
| Wambeke David J. | DMAC | Chief Business Officer | Nov 16 '23 | Buy | $2.46 | 20,000 | $49,200.00 | 527,114 | SEC Form 4 |
Latest DiaMedica Therapeutics Inc. News
DMAC Breaking Stock News: Dive into DMAC Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 50% ownership, insiders own 39%
Business Wire
16 days ago
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Business Wire
a month ago
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
Business Wire
a month ago
DiaMedica Therapeutics Announces $11.8 Million Private Placement
Business Wire
a month ago
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
Simply Wall St.
2 months ago
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Insider Monkey
2 months ago
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript
Business Wire
3 months ago
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
Compare DMAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DMAC DiaMedica Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.